Lead Product(s) : NOV004
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups. Additionally, bone deposition and max load doubled and the force required to refracture the bones increased more than two-fold in mouse models.
Product Name : NOV004
Product Type : Peptide
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : NOV004
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HST-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has verbally notified the company that it has additional questions about the company’s IND application package for the planned Phase 1/2 clinical trial of HST-003.
Product Name : HST-003
Product Type : Protein
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : HST-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable